Anlon Healthcare IPO Date, Review, Price and Key Information

Anlon Healthcare Limited IPO is fully book build issue and it is fully fresh issue offer. The total offering consists of 1.4 crore shares.

The dates for the Anlon Healthcare IPO have not been announced yet.

The allotment process is expected to be finalized by [.]. The Anlon Healthcare IPO is scheduled to list on BSE, NSE, with a tentative listing date of [.].

The price band for the Anlon Healthcare IPO has not been announced yet.

Registrar for this IPO is KFin Technologies Limited and lead managers for Anlon Healthcare IPO are Interactive Financial Services Limited.

IPO Schedule

IPO Open Date	-
IPO Close Date	-
IPO Allotment Date	-
Refund Initiation	-
Share credit in Demat	-
Listing Date	-

Key Details

Price Band	TBA
Lot Size	TBA
Face Value	₹10 Per Equity Share
Total Issue Size	14,000,000 Shares
Fresh Issue	14,000,000 Shares
Issue Type	Fresh Issue
Listing At	BSE, NSE

Share Reservation

Investor Category	Shares Offered
QIB	75%
Retail	10%
NII/HNI	15%

About Anlon Healthcare Limited Company

Anlon Healthcare Limited is a chemical manufacturing company specializing in high-purity pharmaceutical intermediates and active pharmaceutical ingredients (APIs). These serve as crucial raw materials for various formulations, nutraceuticals, personal care products, and animal health products. Their API products are manufactured in compliance with Indian and international standards.

A key product is Loxoprofen Sodium Dihydrate, a widely used API for pain and inflammation treatment. Anlon Healthcare also provides custom manufacturing services for complex chemical compounds, ensuring purity levels that exceed industry standards. They have approvals for Drug Master Files (DMF) from agencies in Brazil, China and Japan, with multiple filings across European Union, Russia and other countries.

As of the date of this document, the product portfolio comprises 65 commercialized products, 28 in the pilot stage, and 49 in laboratory testing. For FY24, Anlon Healthcare reported a total income of ₹66.69 Lakhs and a net profit of ₹9.65 Lakhs. The company focuses on expanding its product portfolio, improving cost management, and maintaining a safe workplace.

Anlon Healthcare Limited Financial Details

Period Ended	30 Jun 2024	31 Mar 2024	31 Mar 2023	31 Mar 2022
Assets	1485.69	1280.01	1115.48	849.72
Revenue	378.33	665.84	1128.77	571.43
Profit After Tax	45.37	96.57	58.20	-1.08
Net Worth	255.68	210.31	73.74	15.54
Reserves and Surplus	95.68	50.31	-46.26	-104.46
Total Borrowing	729.27	745.63	663.87	603.23

₹ In Crore

Key Performance Indicator

Basic EPS (in ₹)	Return on Net Worth (RoNW)	Net Asset Value (NAV)	Debt-Equity Ratio	Return on Equity (ROE)	Return on Capital Employed (ROCE)
6.68	45.92%	13.14	3.55	0.98	16.29%

Offer Objectives

The company intends to utilize the net proceeds from its IPO, amounting to ₹[●] lakhs, for several key objectives. Primarily, ₹30.7195 crore is allocated for funding capital expenditure for the Proposed Expansion of the Manufacturing Facility.

Furthermore, ₹5 crore is earmarked for the full or partial repayment and/or prepayment of certain outstanding secured borrowings. A significant portion, ₹35.98 crore, is designated for funding the working capital requirements of the company. Finally, a portion of the funds will be utilized for General corporate purposes, not exceeding 25% of the Gross Proceeds.

The Proposed Expansion involves establishing a new manufacturing plant with an installed capacity of 700 MTPA, increasing the total capacity to 1,100 MTPA. The estimated cost for the Proposed Expansion is ₹30.7195 crore, including ₹3.2195 crore for civil and structural work and ₹27.50 crore for equipment, plant, and machinery.The schedule for implementation of the Proposed Expansion is expected to be completed on or before March 31, 2026.

The company anticipates benefits from the listing, including enhanced visibility, brand image, and a public market for its Equity Shares.